of the patients, without significant difference between concurrent and sequential CRT. Acute grade 3 esophageal toxicity occurred in 5.5% of patients overall; and was significantly worse (p<0.01) in patients treated with concomitant CRT compared to sequential CRT: 10.4% vs. 4.3% respectively. Late grade 2 pulmonary and esophageal toxicity was observed in 3.3% and 0% respectively; late grade 2 toxicity in 13.2% and 1.4% of the cases respectively. Although there was a trend towards reduced esophageal toxicity, the use of standardized dose-volume evaluation criteria (N=38) did not influence pulmonary (p=0.60) nor esophageal (p=0.08) toxicity significantly.

Conclusion: In spite of the low 5-year OS in patients undergoing sequential CRT, the entire NSCLC population treated with IMRT in our institution obtained OS in line with that reported in the literature. IMRT further confirms the potential for reduced toxicity as observed in other single-center experiences. Regardless of the lack of documented significant impact, we are convinced that the use of standardized dose-volume evaluation criteria has contributed to this positive outcome and is a pre-condition to exploit the full potential of IMRT in NSCLC.

Table: Patient, tumor and treatment characteristics (n = 2229)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Number</th>
<th>Percentage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>Male</td>
<td>1125</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>1085</td>
</tr>
<tr>
<td>RT method</td>
<td>CRT</td>
<td>1125</td>
</tr>
<tr>
<td></td>
<td>RT</td>
<td>1085</td>
</tr>
<tr>
<td>Primary tumor characteristics</td>
<td>}</td>
<td>}</td>
</tr>
<tr>
<td></td>
<td></td>
<td>}</td>
</tr>
<tr>
<td></td>
<td></td>
<td>}</td>
</tr>
<tr>
<td></td>
<td></td>
<td>}</td>
</tr>
</tbody>
</table>
| Material and Methods: Between 2002 and 2013, a total of 434 patients with a thoracic malignancy have been treated with IMRT in the Radiation Oncology department of the Ghent University Hospital. Those with NSCLC and receiving a total dose of 60Gy with fraction size <3Gy, a total 223, were retrospectively reviewed and formed the basis of this analysis. Clinical endpoints of OS and acute and late pulmonary and esophageal toxicity grade ≥3 were analyzed in relation to chemotherapy (concomitant vs. sequential chemoradiotherapy (CRT) vs. no chemotherapy) and use of standardized dose-volume evaluation criteria. Analysis was performed in SPSS using Kaplan-Meier curves for survival and Chi-square analysis for toxicity.

Results: Median follow-up time is 18 months (range 2-125). The table reports patient, tumor and treatment characteristics. OS was scored for all patients as date of death (N=140) or, if missing, as date of last consultation in our hospital (N=83). Acute and late toxicity data were available for 219 and 95 patients respectively. Median OS for the entire population was 25 months, 5 year OS 24%. OS was significantly better for patients treated with concomitant CRT than for those undergoing the sequential approach (median OS 30 months vs. 23; 5 years OS 32% vs. 12%) (p<0.05). Acute grade ≥3 pulmonary toxicity occurred in 7.8%
Results: Two hundred seventeen NSCLC patients were treated in our center. In fifty cases there was a volume reduction, so a ‘replanning’ was outlined. Patients’ characteristics include: mean age 64 years, squamous histology 56%, 32% adenocarcinoma, other 12%, stage IIA 58% and IIIB 42%. The median total dose delivered was 65.7 Gy with standard fractionation. Median CTV at CT simulation and at ‘replanning’ was 125.2 cc and 74.7 cc, respectively, with a median reduction of 43.1%. The ‘replanning’ has been performed at a median dose of 45 Gy. At first follow up, 48 patients were evaluated. Response, according to RECIST criteria, was as follow: 2 complete responses (4.1%), 33 partial responses (68.8%) and 13 stable disease (27.1%). Grade 3 toxicities (CTCAE 4.0) were: anorexia in 4% of cases, pulmonary 6% (1 case acute and 2 chronic). With a median follow-up of 20.5 months, there have been 15 local (31%) and 22 distant (46%) failures. The observed local failures were: in field in 20.8% of cases, ‘marginal’ in 6.1% and out of field in 4.1%. The median time to local failure, progression free survival and overall survival was 8.5, 8.3 and 30.5 months, respectively. The median onset of “marginal”, in field, out of field and distant failures was 12, 9.2, 7.1 and 7.8 months, respectively.

Conclusion: Our results show that ‘replanning” during RCT has an acceptable local failure rate comparable to literature data; in particular, given the low incidence of ‘marginal’ failures combined with the low rate of acute toxicity, the strategy appears promising, bringing to a method of dose escalation aimed at reducing in field failures.

PV-0277
SBRT with concurrent chemoradiation in stage III NSCLC: first results of the phase I Hybrid trial
Netherlands Cancer Institute, Radiation Oncology, Amsterdam, The Netherlands

Purpose or Objective: To assess the feasibility and safety of combined stereotactic body radiotherapy (SBRT) of the primary tumor (PT) and concurrent chemoradiation (CCRT) in stage III NSCLC, the Hybrid study (single center phase I: NCT01933568) was initiated. Primary endpoint is the mean lung dose (MLD) associated with 15% chance on radiation pneumonitis (RP): G3 and dyspnea ≥ G3. Secondary endpoints are toxicity and disease control. This is the first report of adverse events observed.

Material and Methods: Eligible patients had stage III or inoperable stage II NSCLC with a peripheral PT < 5 cm. Patient received CCRT: 24x2.75 Gy or 24x2.42 Gy on the pathological lymph nodes (LN) daily low dose cisplatinum 6 mg/m2 with an overall treatment time of 32 days. SBRT was delivered in 3 fractions of 14-18 Gy in the 2nd week concurrent with CCRT. If the fractionated LN treatment plan contributed to the PT dose, the total SBRT dose was corrected for accordingly. The MLD was escalated with 2 Gy increments using the Time-to-Event Continuous Reassessment Method (TITE-CRM) statistical design driven by dose limiting toxicity (RP or dyspnea: G3; CTCAE v4) within 12 months post treatment. The range of acceptable SBRT fraction doses allowed accruing patients in different MLD dose bins.

Results: From March 2013- October 2015 12 patients gave informed consent for the trial. One patient was excluded after the 1st week of treatment due to a baseline shift of the PT towards the mediastinum, causing unacceptable dose to the mediastinal organs at risk (OAR) if treated with SBRT. Median follow up (FU) was 8 months (range 0-26), median age was 63 years (range 61-75), 73% was male, 73% had adenocarcinoma, 18% squamous cell carcinoma, 9% large cell NOS. 73% had T1 tumors, 9% T2, 18% T3 (2 tumors), 18% N1, 73% N2 and 9% N3. Ten patients received CCRT, 1 patient radiotherapy only due to co-morbidities. No locoregional recurrences have been observed. Two patients developed distant metastases, one of which died 12 months post treatment due to leptomeoginal metastases. Median SBRT dose was 53 Gy (range 43-54 Gy) and median LN dose was 2.75 Gy. Median MLD (α/β= 3 Gy) was 11.9 Gy (range 5.2-18 Gy). In 2 patients SBRT dose was decreased: in 1 patient due to allocated in a lower MLD risk group than the treatment plan MLD, in 1 patient because of normal tissue constraints of the mediastinal OAR. During treatment 4 patient developed dysphagia G2, 2 fatigue G2, 1 thrombocytopenia G2, 1 anorexia G2 and 1 patient hemoptysis G2 . Radiation pneumonitis G2 occurred in 1 patient at 2.5 months FU with an MLD of 12.4 Gy. One patient developed chest wall pain G2 due to a rib fracture at 32 months FU. There were no G3-5 toxicities.

Conclusion: A Hybrid treatment of SBRT of the primary tumor combined with concurrent chemoradiation is feasible. This phase I trial is currently accruing and no unexpected toxicity has been observed thus far.

PV-0278
Volume concepts in routine radiotherapy for localized Hodgkin lymphoma: results of a national survey
1Institut Gustave Roussy, Department of Radiation Oncology, Villejuif, France
2Institut Paoli Calmette, Radiation Oncology, Marseille, France
3Centre GF Leclerc, Radiation Oncology, Dijon, France
4CHU Godinne, Radiation Oncology, Namur, Belgium
5Institut de Cancérologie de Lorraine, Radiation Oncology, Vandœuvre-lès-Nancy, France
6Institut Curie, Radiation Oncology, Saint-Cloud, France
7Gustave Roussy, Hematology, Villejuif, France
8Institut Curie, Nuclear Medicine, Saint-Cloud, France

Purpose or Objective: Background The definition of target volumes in radiotherapy for Hodgkin lymphoma quickly evolved during the last decades, with the comings of involved-field radiotherapy (IF), then the Involved Node (IN)1, and more recently the concept of Involved –site (IS)2. The latter two concepts are based on the observation that recurrences mainly concern the adenopathies present at diagnosis when radiotherapy is not performed and on the need to reduce the irradiated volumes to limit the radiation-induced late morbidity. If the IF and IS concepts were based on the observation that recurrences mainly concern the adenopathies present at diagnosis when radiotherapy is not performed and on the need to reduce the irradiated volumes to limit the radiation-induced late morbidity. If the H103 and RAPID studies confirmed the interest of radiotherapy in localized disease, the standard technique is still debated. The studies currently led by the LYSIA illustrate this confusion since one (BREACH) made I the standard technique, while the other (BRAPP2) requires IF-radiotherapy.

To assess routine radiotherapy practices in the treatment of localized Hodgkin lymphoma.

Material and Methods: At the initiative of multicentric and multidisciplinary working group involving radiation oncologists, hematologists, and nuclear medicine physicians,